RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
Clinical trials for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug takes on tough blood cancers
Disease control TerminatedThis early-stage trial tested a new drug called NC525 in people with advanced myeloid neoplasms, including relapsed or refractory acute myeloid leukemia. The main goal was to check safety and tolerability, with a secondary focus on whether the drug could shrink tumors or improve …
Matched conditions: RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug BR108 tested in blood cancer patients – early results uncertain
Disease control TerminatedThis early-phase study tested an experimental drug called BR108 in 8 adults with advanced blood cancers (lymphoma, leukemia, or myelodysplastic syndrome) that had not responded to prior treatments. The drug was given by IV infusion twice per cycle. The main goals were to check sa…
Matched conditions: RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC